Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.…
Vita Life Sciences And 2 Other Australian Biotech Stocks To Own
Clinuvel Pharmaceuticals (NASDAQ: CUVL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 4.620 USD on 20 November 2026, down 35.4% over 52 weeks. Its 52-week range is 4.536 USD to 8.920 USD: the price is 48.2% below the high and 1.9% above the low.
At a market capitalisation of 233.25M USD, it trades at 10.3 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 69% for CUVL. It pays a dividend yielding 0.75% (it pays out 8% of its earnings), against a median of 0.95% among the dividend payers in that peer group.
Clinuvel Pharmaceuticals reports return on equity of 12.4%, an operating margin of 43.1% and revenue down 3.8% year over year.
It holds more cash than debt, a net cash position of 250.12M AUD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.
No upcoming events tracked.